RhumbLine Advisers
VRDN icon

RhumbLine Advisers’s Viridian Therapeutics VRDN Stock Holding History

RhumbLine Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Buy
117,747
+17,714
+18% +$285K ﹤0.01% 1898
2026
Q1 		$1.96M Buy
100,033
+2,582
+3% +$76.7K ﹤0.01% 1874
2025
Q4 		$3.03M Sell
97,451
-6,909
-7% -$189K ﹤0.01% 1654
2025
Q3 		$2.25M Sell
104,360
-3,025
-3% -$54.6K ﹤0.01% 1843
2025
Q2 		$1.5M Buy
107,385
+2,826
+3% +$38.4K ﹤0.01% 2039
2025
Q1 		$1.41M Buy
104,559
+4,621
+5% +$78.7K ﹤0.01% 1998
2024
Q4 		$1.92M Buy
99,938
+11,594
+13% +$252K ﹤0.01% 1899
2024
Q3 		$2.01M Sell
88,344
-2,482
-3% -$40.6K ﹤0.01% 1910
2024
Q2 		$1.18M Buy
90,826
+23,305
+35% +$323K ﹤0.01% 2152
2024
Q1 		$1.18M Buy
67,521
+7,087
+12% +$137K ﹤0.01% 2163
2023
Q4 		$1.32M Sell
60,434
-63
-0.1% -$995 ﹤0.01% 2124
2023
Q3 		$928K Buy
60,497
+1,015
+2% +$19.4K ﹤0.01% 2252
2023
Q2 		$1.42M Buy
59,482
+6,514
+12% +$167K ﹤0.01% 2105
2023
Q1 		$1.35M Buy
52,968
+5,715
+12% +$183K ﹤0.01% 2005
2022
Q4 		$1.38M Buy
47,253
+12,390
+36% +$285K ﹤0.01% 1979
2022
Q3 		$715K Buy
34,863
+3,150
+10% +$56.6K ﹤0.01% 2328
2022
Q2 		$367K Buy
+31,713
New +$426K ﹤0.01% 2647
2019
Q2 		– Sell
-2,184
Closed -$91K – 3006
2019
Q1 		$91K Sell
2,184
-39
-2% -$1.76K ﹤0.01% 2870
2018
Q4 		$101K Buy
2,223
+754
+51% +$43.6K ﹤0.01% 2882
2018
Q3 		$123K Sell
1,469
-54
-4% -$5.09K ﹤0.01% 2839
2018
Q2 		$146K Buy
1,523
+667
+78% +$70.5K ﹤0.01% 2814
2018
Q1 		$90K Buy
856
+180
+27% +$19.6K ﹤0.01% 2756
2017
Q4 		$106K Sell
676
-153
-18% -$19.5K ﹤0.01% 2766
2017
Q3 		$114K Buy
829
+24
+3% +$4.04K ﹤0.01% 2853
2017
Q2 		$156K Buy
+805
New +$136K ﹤0.01% 2827

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RhumbLine Advisers's VRDN Position: Q2 2026 in Review

RhumbLine Advisers increased its Viridian Therapeutics (VRDN) stake by 18% in Q2 2026, buying an estimated $285K and bringing the position to 117,747 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

RhumbLine Advisers first reported a position in VRDN in Q2 2017 and has held it in 25 quarters since. The position peaked at $3.03M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • RhumbLine Advisers held 117,747 shares of Viridian Therapeutics worth $2.16M as of Q2 2026.
  • RhumbLine Advisers bought 17,714 Viridian Therapeutics shares in Q2 2026, an estimated $285K.
  • Viridian Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1898 holding.
  • RhumbLine Advisers first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 25 quarters since.
  • RhumbLine Advisers's Viridian Therapeutics position peaked at $3.03M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.